Abstract

Estrogen is instrumental in the pathological process of osteoporosis because a deficiency of this hormone increases the release of bone-resorbing cytokines. Acetyl-11-keto-β-boswellic acid (AKBA), a constituent from Boswellia serrata, has an anti-inflammatory effect by inhibiting tumor necrosis factor-α (TNF-α) expression, which leads to a decline in receptor activator of nuclear factor-kappa B (NF-κB) ligand, and consequently, a reduction in osteoclast activity. Hence, AKBA may be beneficial against bone loss during osteoporosis. Therefore, the current study intended to evaluate the beneficial effects of AKBA in ovariectomy-induced osteoporosis and to investigate its mechanism of action. Sham-operation or ovariectomy female Sprague Dawley rats were used for evaluating the antiosteoporotic effect of AKBA in this study. AKBA (35 mg/kg, p.o.) and estradiol (0.05 mg/kg, i.m.) were administered for 42 days. At the end of the experiment, body and uterus weights, serum and urine calcium and phosphorus, serum alkaline phosphatase, and urinary creatinine levels, besides serum levels of NF-κB and TNF-α were determined. Weight, length, thickness, hardness, calcium content, as well as the bone mineral density of femur bone and lumbar vertebra were measured. A histopathological examination was also carried out. AKBA ameliorated all tested parameters and restored a normal histological structure. Thus, AKBA showed good antiosteoporotic activity, which may be mediated through its suppression of the NF-κB-induced TNF-α signaling pathway.

Highlights

  • Osteoporosis, a pandemic health issue affecting generally postmenopausal women, is a systemic skeletal disease known with decreased bone mineral density (BMD) and micro-architectural impairment of the quality of bone tissue [1]

  • The results of ovariectomy group indicate significant surge in body weight together with significantly decreased uterine weight when compared with the sham-operated group

  • Acetyl-11-keto-β-boswellic acid (AKBA) and estradiol-treated animals have shown a substantial (p < 0.01) rise in uterine weight in comparison to the disease control group, while there was an insignificant change in body weight by treatment with

Read more

Summary

Introduction

Osteoporosis, a pandemic health issue affecting generally postmenopausal women, is a systemic skeletal disease known with decreased bone mineral density (BMD) and micro-architectural impairment of the quality of bone tissue [1]. This debilitating condition of osteoporosis leads to a higher risk of bone brittleness and vulnerability to fracture and is associated with morbidity, mortality, and a reduction in quality of life [2]. Estrogen plays a pivotal role in the pathological process of postmenopausal osteoporosis because the deficiency of this chief hormone increases the release of bone-resorbing cytokines, which appears to increase the osteoclast activity [3]. Anti-resorptive and anabolic agents are extensively used for the treatment of osteoporosis. Extensive studies has agents are extensively for the treatment of osteoporosis

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call